Page last updated: 2024-09-04
canertinib and ag-879
canertinib has been researched along with ag-879 in 1 studies
Compound Research Comparison
| Studies (canertinib) | Trials (canertinib) | Recent Studies (post-2010) (canertinib) | Studies (ag-879) | Trials (ag-879) | Recent Studies (post-2010) (ag-879) |
|---|---|---|---|---|---|
| 124 | 9 | 65 | 57 | 0 | 21 |
Protein Interaction Comparison
| Protein | Taxonomy | canertinib (IC50) | ag-879 (IC50) |
|---|---|---|---|
| Receptor tyrosine-protein kinase erbB-2 | Homo sapiens (human) | 1 | |
| High affinity nerve growth factor receptor | Homo sapiens (human) | 10 | |
| Ephrin type-A receptor 3 | Mus musculus (house mouse) | 0.005 |
Research
Studies (1)
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
Authors
| Authors | Studies |
|---|---|
| Bharate, SB; Raghuvanshi, R | 1 |
Other Studies
1 other study(ies) available for canertinib and ag-879
| Article | Year |
|---|---|
Recent Developments in the Use of Kinase Inhibitors for Management of Viral Infections.
Topics: Antiviral Agents; COVID-19; COVID-19 Drug Treatment; Drug Approval; Drug Repositioning; High-Throughput Screening Assays; Humans; Protein Kinase Inhibitors; SARS-CoV-2; United States; United States Food and Drug Administration; Virus Diseases | 2022 |